Affordable Access

Publisher Website

Metformin for Obesity in Children and Adolescents: A Systematic Review

Authors
Journal
Diabetes Care
0149-5992
Publisher
American Diabetes Association
Publication Date
Volume
32
Issue
9
Identifiers
DOI: 10.2337/dc09-0258
Keywords
  • Reviews/Commentaries/Ada Statements
  • Meta-Analyses
Disciplines
  • Medicine

Abstract

OBJECTIVE To summarize the efficacy of metformin in reducing BMI and cardiometabolic risk in obese children and adolescents without diabetes. RESEARCH DESIGN AND METHODS We performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Double-blind RCTs of ≥6 months duration in obese subjects age ≤19 years without diabetes were included. Our primary outcomes of interest include changes in BMI and measures of insulin sensitivity. RESULTS Five trials met inclusion criteria (n = 320 individuals). Compared with placebo, metformin reduced BMI by 1.42 kg/m2 (95% CI 0.83–2.02) and homeostasis model assessment insulin of resistance (HOMA-IR) score by 2.01 (95% CI 0.75–3.26). CONCLUSIONS Metformin appears to be moderately efficacious in reducing BMI and insulin resistance in hyperinsulinemic obese children and adolescents in the short term. Larger, longer-term studies in different populations are needed to establish its role in the treatment of overweight children.

There are no comments yet on this publication. Be the first to share your thoughts.